Previous Close | 0.0300 |
Open | 0.0310 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's Range | 0.0301 - 0.0320 |
52 Week Range | 0.0300 - 0.3200 |
Volume | |
Avg. Volume | 629,760 |
Market Cap | 4.48M |
Beta (5Y Monthly) | 1.09 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.1330 |
Earnings Date | Nov 14, 2022 - Nov 18, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 0.20 |
Subscribe to Yahoo Finance Plus to view Fair Value for CVSI
CV Sciences, Inc. (OTCQB: CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven, science-backed, natural ingredients and products, today announced the launch of +PlusCBD™Reserve Collection Softgels to support stress relief and relaxation. The product will be available on +PlusCBD's' website on August 15, 2022.
CV Sciences, Inc. (OTCQB: CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced its financial results for the quarter ended June 30, 2022.
SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced its financial results for the quarter ended March 31, 2022. First Quarter 2022 and Recent Financial and Operating Highlights Revenue of $4.4 million for first quarter of 2022, compared to $4.8 million for the first quarter of 2021;Gross margin of 26.0% for first quarter of 2022, c